BCIQ Profiles

Company Profile Report

Tessera: engineering mobile genetic elements for gene insertion

Flagship newco Tessera uses mobile genetic elements to make gene insertions

Tessera Therapeutics, the latest company to emerge from Flagship Pioneering, is developing a suite of gene editing tools based on mobile genetic elements that have the potential to create a broader range of genomic alterations than CRISPR.

The company came out of stealth on Tuesday with over $50 million in funding from Flagship, two years of research supporting its Gene Writing

Read the full 612 word article

How to gain access

Continue reading with a
two-week free trial.